Companies › COMPASS Pathways
1 active drug program in 98 registered trials: 55 Phase 2, 34 Phase 1, 9 Phase 3; Neurology, Immunology, Oncology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Psilocybin (COMP360) Serotonin 2a (5-HT2a) receptor agonist | HTR2A | Phase 3 | Treatment Resistant Depression; Major Depressive Disorder; PTSD - Post Traumatic Stress Disorder; Depressive Disorder, Major … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04410913 | Psilocybin (COMP360) | Phase 2 | Alcohol Use Disorder | Psychiatry | Feb 2023 |
| NCT05421065 | Psilocybin (COMP360) | Phase 2 | Alcohol Use Disorder | Psychiatry | Aug 2025 |
| NCT05733546 | Psilocybin (COMP360) | Phase 2 | Major Depressive Disorder | Psychiatry | Sep 2025 |
| NCT06899334 | Psilocybin (COMP360) | Phase 1 | Healthy | Other | Aug 2026 |
| NCT06796361 | Psilocybin (COMP360) | Phase 1 | Healthy | Other | Aug 2026 |
| NCT05585229 | Psilocybin (COMP360) | Phase 2 | Opioid Dependence | Psychiatry | Aug 2026 |
| NCT07079930 | Psilocybin (COMP360) | Phase 1 | Healthy Volunteers | Other | Nov 2026 |
| NCT06898606 | Psilocybin (COMP360) | Phase 1 | Depressive Disorder | Psychiatry | Nov 2026 |
| NCT07336238 | Psilocybin (COMP360) | Phase 2 | Anxiety | Oncology | Dec 2026 |
| NCT05711940 | Psilocybin (COMP360) | Phase 3 | Treatment Resistant Depression | Psychiatry | Dec 2026 |
| NCT06416085 | Psilocybin (COMP360) | Phase 2 | Advanced Cancer | Oncology | Dec 2026 |
| NCT06319378 | Psilocybin (COMP360) | Phase 2 | MDD | Oncology | Dec 2026 |
| NCT06888128 | Psilocybin (COMP360) | Phase 2 | PTSD | Psychiatry | Dec 2026 |
| NCT06888128 | Psilocybin (COMP360) | Phase 2 | PTSD | Psychiatry | Dec 2026 |
| NCT06731335 | Psilocybin (COMP360) | Phase 2 | Chronic Neuropathic Pain | Neurology | Dec 2026 |
| NCT06225232 | Psilocybin (COMP360) | Phase 2 | Cannabis Use Disorder, Moderate | Oncology | Dec 2026 |
| NCT06815653 | Psilocybin (COMP360) | Phase 1 | Healthy | Other | Dec 2026 |
| NCT06430541 | Psilocybin (COMP360) | Phase 1 | Breast Cancer | Oncology | Dec 2026 |
| NCT03554174 | Psilocybin (COMP360) | Phase 1 | Major Depressive Disorder | Psychiatry | Dec 2026 |
| NCT03554174 | Psilocybin (COMP360) | Phase 1 | Major Depressive Disorder | Psychiatry | Dec 2026 |
| NCT04161066 | Psilocybin (COMP360) | Phase 1 | Opioid Use Disorder | Psychiatry | Dec 2026 |
| NCT06341426 | Psilocybin (COMP360) | Phase 2 | Major Depressive Disorder | Psychiatry | Dec 2026 |
| NCT06367738 | Psilocybin (COMP360) | Phase 1 | Aging | Other | Dec 2026 |
| NCT05403086 | Psilocybin (COMP360) | Phase 2 | Demoralization | Psychiatry | Dec 2026 |
| NCT06378229 | Psilocybin (COMP360) | Phase 2 | Treatment Resistant Depression | Psychiatry | Dec 2026 |
| NCT06200155 | Psilocybin (COMP360) | Phase 2 | Depression, Anxiety | Psychiatry | Dec 2026 |
| NCT06001749 | Psilocybin (COMP360) | Phase 2 | Opioid-Related Disorders | Oncology | Dec 2026 |
| NCT04982796 | Psilocybin (COMP360) | Phase 1 | Amphetamine-Related Disorders | Psychiatry | Dec 2026 |
| NCT05398484 | Psilocybin (COMP360) | Phase 2 | Advanced Cancer | Oncology | Jan 2027 |
| NCT06782724 | Psilocybin (COMP360) | Phase 2 | COPD (Chronic Obstructive Pulmonary Disease) | Neurology | Jan 2027 |
| NCT06506019 | Psilocybin (COMP360) | Phase 1 | Bipolar Depression | Psychiatry | Jan 2027 |
| NCT04754061 | Psilocybin (COMP360) | Phase 1 | Depression, Anxiety | Psychiatry | Jan 2027 |
| NCT06731621 | Psilocybin (COMP360) | Phase 1 | Treatment Resistant Depression | Psychiatry | Jan 2027 |
| NCT06160284 | Psilocybin (COMP360) | Phase 1 | Opioid Use Disorder | Psychiatry | Jan 2027 |
| NCT06308653 | Psilocybin (COMP360) | Phase 3 | Depressive Disorder, Major | Psychiatry | Jan 2027 |
| NCT05698511 | Psilocybin (COMP360) | Phase 1 | Psychedelic Experiences | Other | Jan 2027 |
| NCT05370911 | Psilocybin (COMP360) | Phase 1 | Obsessive-Compulsive Disorder | Psychiatry | Feb 2027 |
| NCT06518720 | Psilocybin (COMP360) | Phase 2 | Treatment Resistant Depression | Psychiatry | Mar 2027 |
| NCT07332143 | Psilocybin (COMP360) | Phase 2 | PTSD | Psychiatry | Mar 2027 |
| NCT06303739 | Psilocybin (COMP360) | Phase 3 | Refractory Depression | Psychiatry | Mar 2027 |
| NCT06801041 | Psilocybin (COMP360) | Phase 2 | Depression | Oncology | Mar 2027 |
| NCT06512220 | Psilocybin (COMP360) | Phase 2 | Treatment Resistant Depression | Psychiatry | Apr 2027 |
| NCT05947383 | Psilocybin (COMP360) | Phase 2 | Cancer | Oncology | Apr 2027 |
| NCT06810310 | Psilocybin (COMP360) | Phase 2 | Opioid Use Disorder | Psychiatry | May 2027 |
| NCT07506395 | Psilocybin (COMP360) | Phase 1 | PTSD | Psychiatry | May 2027 |
| NCT04882839 | Psilocybin (COMP360) | Phase 2 | Obsessive-compulsive Disorder | Psychiatry | Jun 2027 |
| NCT07183748 | Psilocybin (COMP360) | Phase 2 | Treatment Resistant Depression | Psychiatry | Jun 2027 |
| NCT06853912 | Psilocybin (COMP360) | Phase 2 | Alcohol Use Disorder (AUD) | Psychiatry | Jun 2027 |
| NCT06786325 | Psilocybin (COMP360) | Phase 2 | Opioid Use Disorder | Psychiatry | Jun 2027 |
| NCT06455293 | Psilocybin (COMP360) | Phase 2 | Parkinson Disease | Neurology | Jun 2027 |
| NCT07063862 | Psilocybin (COMP360) | Phase 3 | Psychological Distress | Other | Aug 2027 |
| NCT06233344 | Psilocybin (COMP360) | Phase 2 | Mental Health | Psychiatry | Aug 2027 |
| NCT07169747 | Psilocybin (COMP360) | Phase 2 | Anorexia Nervosa | Psychiatry | Oct 2027 |
| NCT07703722 | Psilocybin (COMP360) | Phase 3 | Major Depressive Disorder | Psychiatry | Oct 2027 |
| NCT07216404 | Psilocybin (COMP360) | Phase 2 | Lung Non-Small Cell Carcinoma | Oncology | Oct 2027 |
| NCT06902974 | Psilocybin (COMP360) | Phase 2 | Post Traumatic Stress Disorder | Psychiatry | Nov 2027 |
| NCT07818564 | Psilocybin (COMP360) | Phase 1 | Phase I | Other | Nov 2027 |
| NCT05866471 | Psilocybin (COMP360) | Phase 1 | Healthy | Other | Nov 2027 |
| NCT06626139 | Psilocybin (COMP360) | Phase 2 | Healthy Participants With Lower-than-average Mental Well-being | Other | Nov 2027 |
| NCT07281352 | Psilocybin (COMP360) | Phase 1 | Major Depressive Diorder | Psychiatry | Nov 2027 |
The 60 nearest readouts of 98 trials; the rest in the app.
Cash of $444m on 2026-09-30; operating cash outflow about $187m a year; runway about 29 months at that burn, to Feb 2029; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Cybin IRL Lipocine Cartesian Therapeutics Xenon Pharmaceuticals Laboratorios Silanes S.A. de C.V.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.